AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 313353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial vasopressin (IAV) started at 0.1 U/min, increased to 0.5 U/min as needed
Number of subjects: 22
Study 31640486 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobility salience condition (completed a mobility perception scale)
Number of subjects: 215
Study 31640486 — intervention group
Group type: COMPARATOR
Intervention: Neutral scale condition (control group)
Number of subjects: 215
Study 31319060 — intervention group
Group type: EXPERIMENTAL
Intervention: AmplifEYE
Number of subjects: 0
Study 31319060 — intervention group
Group type: COMPARATOR
Intervention: Endocuff Vision
Number of subjects: 0
Study 28397083 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐RME on second deciduous molars (GrE)
Number of subjects: 70
Study 28397083 — intervention group
Group type: COMPARATOR
Intervention: H‐RME on first permanent molars (Gr6)
Number of subjects: 70
Study 25664323 — intervention group
Group type: EXPERIMENTAL
Intervention: AndoSan (mushroom extract containing 82% Agaricus blazei Murrill)
Number of subjects: 40
Study 25664323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25415862 — intervention group
Group type: EXPERIMENTAL
Intervention: Training course for screening obstetric ultrasound (10-day course with quality assurance activities)
Number of subjects: 0
Study 23032746 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib (GDC‐0449; 150 mg daily)
Number of subjects: 104
Study 23032746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 23032746 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib
Number of subjects: 104
Study 19676125 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 microg PEG‐IFNalpha‐2a weekly plus ribavirin at 1000‐1200 mg/day for 12 weeks
Number of subjects: 896
Study 19676125 — intervention group
Group type: COMPARATOR
Intervention: 180 microg PEG‐IFNalpha‐2a weekly plus ribavirin at 1000‐1200 mg/day for 12 weeks
Number of subjects: 896
Study 17166775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) adjunctive treatment
Number of subjects: 158
Study 15850856 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counseling and print materials
Number of subjects: 450
Study 15850856 — intervention group
Group type: COMPARATOR
Intervention: Print materials alone
Number of subjects: 450
Study 12072599 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole MUPS 20 mg
Number of subjects: 461
Study 12072599 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 461
Study 12072599 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 461
Study 9594927 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid altering or antioxidant vitamins
Number of subjects: 0
Study 9594927 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8934728 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC with high-dose infusional 5-fluorouracil (750 mg/m2 per day/days 1 to 5)
Number of subjects: 178
Study 8934728 — intervention group
Group type: COMPARATOR
Intervention: Standard FEC regimen (5‐FU 500 mg/m2, epirubicin 50 mg/m2, cyclophosphamide 500 mg/m2)
Number of subjects: 178
Study 8934728 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC with high-dose infusional 5-fluorouracil
Number of subjects: 178
Study 8934728 — intervention group
Group type: COMPARATOR
Intervention: Standard FEC regimen
Number of subjects: 178
Study 2235919 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal occult blood test performance after initial test mailing and follow-up mailing.
Number of subjects: 504
Study 2235919 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal occult blood testing among past nontesters (n = 121).
Number of subjects: 504
Study 2235919 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal occult blood testing among past testers (n = 201).
Number of subjects: 504
Study 233444 — intervention group
Group type: EXPERIMENTAL
Intervention: tiapride 300 mg/day
Number of subjects: 30
Study 30157242 — intervention group
Group type: EXPERIMENTAL
Intervention: subtype C prophylactic vaccine (DNA prime: ADVAX and MVA boost: TBC-M4)
Number of subjects: 0
Study 26498057 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone solution 2% (60 mg topical, once daily)
Number of subjects: 715
Study 26498057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 715
Study 26498057 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone solution 2%
Number of subjects: 715
Study 24353345 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher erythrocyte membrane eicosapentaenoic acid proportions
Number of subjects: 390
Study 24353345 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher current fish consumption
Number of subjects: 390
Study 24353345 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater fish consumption in childhood
Number of subjects: 390
Study 24353345 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher proportions of long-chain n-3 fatty acids or fish intake
Number of subjects: 390
Study 23427383 — intervention group
Group type: EXPERIMENTAL
Intervention: Liandouqingmai Recipe
Number of subjects: 101
Study 23427383 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 101
Study 20409627 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsim e-learning programme
Number of subjects: 572
Study 20409627 — intervention group
Group type: COMPARATOR
Intervention: Control group (course manual and pre-course MCQ)
Number of subjects: 572
Study 18712644 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined electroacupuncture and strength training
Number of subjects: 10
Study 18712644 — intervention group
Group type: COMPARATOR
Intervention: Strength training alone
Number of subjects: 10
Study 15992754 — intervention group
Group type: EXPERIMENTAL
Intervention: 1CU accommodative IOL
Number of subjects: 30
Study 15992754 — intervention group
Group type: COMPARATOR
Intervention: Acrysof MA30 monofocal IOL
Number of subjects: 30
Study 12088970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal Fentanyl (12 mg of hyperbaric bupivacaine plus 12.5 microg of fentanyl)
Number of subjects: 48
Study 12088970 — intervention group
Group type: COMPARATOR
Intervention: IV Fentanyl (12.5 microg administered immediately after spinal anesthesia)
Number of subjects: 48
Study 12088970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal Fentanyl
Number of subjects: 48
Study 12088970 — intervention group
Group type: COMPARATOR
Intervention: IV Fentanyl
Number of subjects: 48
Study 10893091 — intervention group
Group type: EXPERIMENTAL
Intervention: NCPAP set at therapeutic levels of pressure
Number of subjects: 101
Study 10893091 — intervention group
Group type: COMPARATOR
Intervention: NCPAP set at sub‐therapeutic pressure levels
Number of subjects: 101
Study 8968156 — intervention group
Group type: EXPERIMENTAL
Intervention: RT‐23 (2 TU PPD)
Number of subjects: 98
Study 8968156 — intervention group
Group type: COMPARATOR
Intervention: 5 TU PPD
Number of subjects: 98
Study 1844926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bolus feeding via nasogastric tube (Group A)
Number of subjects: 42
Study 1844926 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous drip feeding via nasogastric tube (Group B)
Number of subjects: 42
Study 1844926 — intervention group
Group type: COMPARATOR
Intervention: Ad-libitum feeding by oral route (Group C)
Number of subjects: 42
Study 6499512 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg spiramycin 3-times daily for 3 days
Number of subjects: 64
Study 6499512 — intervention group
Group type: COMPARATOR
Intervention: 500 mg erythromycin 3-times daily for 5 days
Number of subjects: 64
Study 28965157 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to Holy Quran recitation (HQR) for 30 minutes
Number of subjects: 55
Study 28965157 — intervention group
Group type: COMPARATOR
Intervention: Control group with 30 minutes of rest in bed
Number of subjects: 55
Study 30291997 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day CHW intervention
Number of subjects: 1200
Study 30291997 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no CHW)
Number of subjects: 1200
Study 26853792 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine gel+lidocaine spray
Number of subjects: 180
Study 26853792 — intervention group
Group type: EXPERIMENTAL
Intervention: base lubricant gel+lidocaine spray
Number of subjects: 180
Study 26853792 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine gel+isotonic spray
Number of subjects: 180
Study 25759182 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision support program
Number of subjects: 113
Study 22429264 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with reverse remodeling
Number of subjects: 119
Study 22429264 — intervention group
Group type: COMPARATOR
Intervention: Non-responders to CRT
Number of subjects: 119
Study 20230067 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting program
Number of subjects: 85
Study 20230067 — intervention group
Group type: COMPARATOR
Intervention: Control task with intervention-quality face validity
Number of subjects: 85
Study 18373315 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVHDF (pre-dilution volume of 600 mls/h with a dialysate dose of 1 L)
Number of subjects: 45
Study 18373315 — intervention group
Group type: COMPARATOR
Intervention: CVVH (ultrafiltrate dose of 35 ml/kg/h)
Number of subjects: 45
Study 16035676 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone cushion (Clinicel)
Number of subjects: 72
Study 16035676 — intervention group
Group type: COMPARATOR
Intervention: Silicone occlusive sheeting
Number of subjects: 72
Study 11932655 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid drainage (CSFD) initiated during the operation and continued for 48 hours after surgery, target CSF pressure 10 mm Hg or less
Number of subjects: 145
Study 11932655 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CSFD)
Number of subjects: 145
Study 11932655 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid drainage (CSFD)
Number of subjects: 145
Study 10086723 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose asparaginase consolidation (25,000 IU/m2) given weekly for 20 weeks by intramuscular injection
Number of subjects: 552
Study 10086723 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (no high-dose asparaginase)
Number of subjects: 552
Study 7724752 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast material concentration of 240 mg of iodine per milliliter
Number of subjects: 200
Study 7724752 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast material volume
Number of subjects: 200
Study 7724752 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast material concentration
Number of subjects: 200
Study 7724752 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated iodine dose based on patient weight
Number of subjects: 200
Study 7724752 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast material concentration of 240 mg I/mL
Number of subjects: 200
Study 2081010 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dietary sodium intake
Number of subjects: 10
Study 2081010 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in serum 1,25-dihydroxyvitamin D
Number of subjects: 10
Study 2081010 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in plasma renin activity
Number of subjects: 10
Study 6356317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (2 tablets of 500 mg 4 times daily)
Number of subjects: 76
Study 6356317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 31062349 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP-825 (22 mg)
Number of subjects: 259
Study 31062349 — intervention group
Group type: COMPARATOR
Intervention: Oral Sumatriptan (100 mg)
Number of subjects: 259
Study 30389036 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P10
Number of subjects: 258
Study 30389036 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 258
Study 26497508 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stress (Trier Social Stress Test, TSST)
Number of subjects: 85
Study 26497508 — intervention group
Group type: COMPARATOR
Intervention: Control session (no stress)
Number of subjects: 85
Study 24570986 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional SRP and diode laser (GaAlAs)‐assisted pocket debridement
Number of subjects: 30
Study 24570986 — intervention group
Group type: COMPARATOR
Intervention: Conventional SRP
Number of subjects: 30
Study 21339698 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration with alternative tilting (WBVAT)
Number of subjects: 53
Study 19462277 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg parecoxib
Number of subjects: 30
Study 19462277 — intervention group
Group type: COMPARATOR
Intervention: Saline-treated control group (placebo)
Number of subjects: 30
Study 21545948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 2908
Study 21545948 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 2908
Study 16418554 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery nursing care using essential oils
Number of subjects: 48
Study 16418554 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study 11826205 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (0.5 mg/kg/d for 3 days)
Number of subjects: 47
Study 11826205 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dexamethasone (0.2 mg/kg/d for 3 days and 0.1 mg/kg/d for 4 days)
Number of subjects: 47
Study 11826205 — intervention group
Group type: EXPERIMENTAL
Intervention: Both high-dose and low-dose dexamethasone
Number of subjects: 47
Study 10811522 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon (flavonoids)
Number of subjects: 19
Study 10811522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8526459 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 1441
Study 8526459 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 1441
Study 2391398 — intervention group
Group type: EXPERIMENTAL
Intervention: flurbiprofen 200 mg plus ranitidine 150 mg bid for 7 days before and for 2 days after receiving flurbiprofen
Number of subjects: 9
Study 2391398 — intervention group
Group type: EXPERIMENTAL
Intervention: flurbiprofen 200 mg plus cimetidine 300 mg qid for 7 days before and for 2 days after receiving flurbiprofen
Number of subjects: 9
Study 2391398 — intervention group
Group type: COMPARATOR
Intervention: flurbiprofen 200 mg
Number of subjects: 9
Study 7029149 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural BCG treatment
Number of subjects: 425
Study 7029149 — intervention group
Group type: COMPARATOR
Intervention: Intrapleural saline (control)
Number of subjects: 425
Study 30376369 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postpartum levonorgestrel-releasing intrauterine device (LNG-IUD) placement
Number of subjects: 63
Study 30376369 — intervention group
Group type: COMPARATOR
Intervention: Interval IUD placement at 6 or more weeks postpartum
Number of subjects: 63
Study 26800177 — intervention group
Group type: COMPARATOR
Intervention: Implants with anodized surfaces (ANO)
Number of subjects: 23
Study 26800177 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants treated by acid (AC)
Number of subjects: 23
Study 25304922 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive feeding regimen (PFR), starting with 100 mL/kg/day and gradually increasing to 200 mL/kg/day by day 4.
Number of subjects: 72
Study 25304922 — intervention group
Group type: COMPARATOR
Intervention: Standard feeding regimen, starting with 60 mL/kg/day and gradually increasing to 170 mL/kg/day by day 9.
Number of subjects: 72
Study 25304922 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive feeding regimen (PFR)
Number of subjects: 72
Study 25304922 — intervention group
Group type: COMPARATOR
Intervention: Standard feeding regimen
Number of subjects: 72
Study 22436957 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous MSC plus standard-dose CNI
Number of subjects: 159
Study 22436957 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous MSC plus low-dose CNI
Number of subjects: 159
Study 22436957 — intervention group
Group type: COMPARATOR
Intervention: Control group (anti-IL-2 receptor antibody plus standard-dose CNI)
Number of subjects: 159
Study 19505968 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 ml kg(‐1) of contrast material (350 mgI ml(‐1)) injected with a fixed duration of 10 s (Group B)
Number of subjects: 45
Study 19505968 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 ml kg(‐1) of contrast material injected with a fixed duration of 14 s (Group A)
Number of subjects: 45
Study 19505968 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 ml kg(‐1) of contrast material injected with a fixed duration of 10 s (Group C)
Number of subjects: 45
Study 18467066 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 0
Study 18467066 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 0
Study 18467066 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Health Counseling
Number of subjects: 0
Study 16437721 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mL of sodium phosphate (NaP) in a split regimen of two 45 mL doses separated by 12 h
Number of subjects: 80
Study 16437721 — intervention group
Group type: COMPARATOR
Intervention: 4 L of polyethylene glycol (PEG)
Number of subjects: 80
Study 16437721 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mL of sodium phosphate (NaP)
Number of subjects: 80
Study 12653815 — intervention group
Group type: EXPERIMENTAL
Intervention: Detoxification with buprenorphine over 3 days
Number of subjects: 123
Study 10475484 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemopump support during coronary artery bypass operations
Number of subjects: 0
Study 10475484 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemopump support during PTCA
Number of subjects: 0
Study 10475484 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemopump in general use
Number of subjects: 0
Study 8604274 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin (ACTH) 150 U/m2/day for 2 weeks
Number of subjects: 29
Study 8604274 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 2 mg/kg/day for 2 weeks
Number of subjects: 29
Study 1720796 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferal (desferrioxamine) 0.1 mg/ml to 100 mg/ml
Number of subjects: 7
Study 1720796 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine 10 mg (H1 antagonist)
Number of subjects: 7
Study 1720796 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferal (desferrioxamine)
Number of subjects: 7
Study 6116097 — intervention group
Group type: EXPERIMENTAL
Intervention: Early return to work after inguinal herniorrhaphy
Number of subjects: 500
Study 30940423 — intervention group
Group type: EXPERIMENTAL
Intervention: I-HAES group (individual nutritional counseling, group practice of enjoyable physical activity, philosophical workshops)
Number of subjects: 43
Study 30940423 — intervention group
Group type: COMPARATOR
Intervention: CTRL group (traditional HAES intervention, lecture-based model)
Number of subjects: 43
Study 30185448 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (δ‐9‐tetrahydrocannabinol)
Number of subjects: 15
Study 30185448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 27383313 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-carbohydrate ketogenic diet (VLCKD) with amino acid supplement (whey protein)
Number of subjects: 25
Study 27383313 — intervention group
Group type: COMPARATOR
Intervention: Very low restricted-calorie diet (VLCD)
Number of subjects: 25
Study 24491642 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized ranibizumab treatment (prior ranibizumab)
Number of subjects: 240
Study 24491642 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized ranibizumab treatment (prior ranibizumab + laser)
Number of subjects: 240
Study 24491642 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment after prior laser
Number of subjects: 240
Study 21982997 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual bowel decompression (milking)
Number of subjects: 40
Study 20882651 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 56
Study 20882651 — intervention group
Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 56
Study 20882651 — intervention group
Group type: COMPARATOR
Intervention: Femoral access during PCI
Number of subjects: 56
Study 20882651 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access during PCI
Number of subjects: 56
Study 18524013 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged surgical approach with temporary femoral stabilization using an external fixator
Number of subjects: 0
Study 18524013 — intervention group
Group type: EXPERIMENTAL
Intervention: Grading system for assessment of clinical status
Number of subjects: 0
Study 15814336 — intervention group
Group type: EXPERIMENTAL
Intervention: THP-COP (pirarubicin, cyclophosphamide, vincristine, and prednisolone)
Number of subjects: 486
Study 15814336 — intervention group
Group type: COMPARATOR
Intervention: Two thirds CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)
Number of subjects: 486
Study 15814336 — intervention group
Group type: EXPERIMENTAL
Intervention: THP-COPE (THP-COP plus etoposide)
Number of subjects: 486
Study 15814336 — intervention group
Group type: EXPERIMENTAL
Intervention: THP-COP
Number of subjects: 486
Study 15814336 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 486
Study 15814336 — intervention group
Group type: EXPERIMENTAL
Intervention: THP-COPE
Number of subjects: 486
Study 15814336 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 486
Study 15814336 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive lymphoma patients
Number of subjects: 486
Study 14720030 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone propionate 50/250 microg (Seretide/Advair) via Diskus inhaler
Number of subjects: 113
Study 14720030 — intervention group
Group type: COMPARATOR
Intervention: budesonide 800 microg (Pulmicort) via Turbuhaler
Number of subjects: 113